tozasertib Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Tozasertib (VX-680) is an aurora inhibitor.   Wikipedia

Chemistry

  • SMILES: Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1
  • InChIKey: GCIKSSRWRFVXBI-UHFFFAOYSA-N
  • Mol. Mass: 464.6
  • ALogP: 3.5
  • ChEMBL Molecule:
    tozasertib  
More Chemistry

Pharmacology

Alternative names

cyclopropane carboxylic acid(4-(4-(4-methylpiperazin-1-yl)-6-(5-methyl-2h-pyrazol-3-ylamino)pyrimidin-2-ylsulfanyl)phenyl)amide | mk-045 | mk0457 | mk-0457 | tozasertib | ve 465 | ve-465 | vx-68 | vx680 | vx-680

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid, Chronic-Phase (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Neoplasms (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue